|本期目录/Table of Contents|

[1]刘国印综述,冷楠楠,陈建民审校.Tim-3介导的免疫调节在类风湿性关节炎中的研究进展[J].医学研究与战创伤救治(原医学研究生学报),2017,19(04):385-389.[doi:10.3969/j.issn.1672-271X.2017.04.013]
点击复制

Tim-3介导的免疫调节在类风湿性关节炎中的研究进展()
分享到62.8K

《医学研究与战创伤救治》（原医学研究生学报）[ISSN:1672-271X/CN:32-1713/R]

卷:
第19卷
期数:
2017年04期
页码:
385-389
栏目:
综述
出版日期:
2017-08-10

文章信息/Info

Title:
-
作者:
刘国印综述; 冷楠楠; 陈建民审校
作者单位：210002南京，南京中医药大学附属八一医院骨科
Author(s):
-
关键词:
免疫哨卡; 免疫调节; 靶向治疗; 类风湿性关节炎; 免疫治疗; 免疫耐受
Keywords:
-
分类号:
R593.22
DOI:
10.3969/j.issn.1672-271X.2017.04.013
文献标志码:
A
摘要:
T细胞免疫球蛋白域黏蛋白域蛋白-3（Tim-3）是负性免疫调节信号，视机体免疫状态的不同而被激活或被抑制，作为类风湿性关节炎（RA）的治疗靶点具有独特优越性。综合最新研究进展，将Tim-3诱导RA的发病机制总结为：在RA活动期，Tim-3持续高表达发挥负向免疫调控作用，从而防止病情的进一步加重。然而，Tim-3的持续高表达能够促进以T细胞为主的免疫细胞功能衰竭，引起免疫耐受紊乱，导致免疫应答增强，增强的免疫应答反应会进一步促进Tim3的高表达，如此恶性循环，最终促进或加重RA的病情进展。文章就Tim-3介导的免疫调节及其靶向治疗在RA发展过程中的作用进行综述。
Abstract:
-

参考文献/References:

[1]Weyand CM, Goronzy JJ. Immunometabolism in early and late stages of rheumatoid arthritis[J]. Nat Rev Rheumatol, 2017, 13(5):291-301.
[2]Misra DP, Agarwal V, Sharma A, et al. 2016 update of the EULAR recommendations for the management of rheumatoid arthritis: a utopia beyond patients in low/middle income countries?[J] Ann Rheum Dis, 2017, pii: annrheumdis-2017-211446.
[3]Humphreys JH, Warner A, Costello R, et al. Quantifying the hepatotoxic risk of alcohol consumption in patients with rheumatoid arthritis taking methotrexate[J]. Ann Rheum Dis, 2017, pii: annrheumdis-2016-210629.
[4]Manivel VA, Mullazehi M, Padyukov L, et al. Anticollagen type II antibodies are associated with an acute onset rheumatoid arthritis phenotype and prognosticate lower degree of inflammation during 5 years follow-up[J]. Ann Rheum Dis, 2017, pii: annrheumdis-2016-210873.
[5]Van den Bosch F, Ostor AJ, Wassenberg S, et al. Impact of Participation in the Adalimumab (Humira) Patient Support Program on Rheumatoid Arthritis Treatment Course: Results from the PASSION Study[J]. Rheumatol Ther, 2017, 4(1):85-96.
[6]Wojcik S, Bernatsky S, Platt RW, et al. Risk of autism spectrum disorders in children born to mothers with rheumatoid arthritis: A systematic literature review[J]. Arthritis Care Res (Hoboken), 2017, doi: 10.1002/acr.23235.
[7]Lin TC, Hashemi N, Kim SC, et al. The practice pattern of hepatitis b testing in rheumatoid arthritis patients: A cross-national comparison between US and Taiwan[J]. Arthritis Care Res (Hoboken), 2017, doi: 10.1002/acr.23241.
[8]van den Brandt S, Zbinden A, Baeten D, et al. Risk factors for flare and treatment of disease flares during pregnancy in rheumatoid arthritis and axial spondyloarthritis patients[J]. Arthritis Res Ther, 2017,19(1):64.
[9]Xu YY, Wang SC, Lin YK, et al. Tim-3 and PD-1 regulate CD8+ T cell function to maintain early pregnancy in mice[J]. Arthritis Res Ther, 2017, 19(1):64.
[10]Mcintire JJ, Umetsu SE, Akbari O, et al. Identification of Tapr (an airway hyperreactivity regulatory locus) and the linked Tim gene family[J]. Nat Immunol, 2001, 2(12):1109-1116.
[11]Granier C, Dariane C, Combe P, et al. Tim-3 Expression on Tumor-Infiltrating PD-1+CD8+ T Cells Correlates with Poor Clinical Outcome in Renal Cell Carcinoma[J]. Cancer Res, 2017,77(5):1075-1082.
[12]Fooladinezhad H, Khanahmad H, Ganjalikhani-Hakemi M, et al. Negative regulation of TIM-3 expression in AML cell line (HL-60) using miR-330-5p[J]. Br J Biomed Sci, 2016, 73(3):129-133.
[13]Wang Z, Liu X, Wang X, et al. Polymorphisms in TIM-3 and breast cancer susceptibility in Chinese women: A case-control study[J]. Oncotarget, 2016, 7(28):43703-43712.
[15]Liu Y, Shu Q, Gao L, et al. Increased Tim-3 expression on peripheral lymphocytes from patients with rheumatoid arthritis negatively correlates with disease activity[J]. Clin Immunol, 2010, 137(2):288-295.
[16]Jiao Z, Hua S, Wang W, et al. Increased circulating myeloid-derived suppressor cells correlated negatively with Th17 cells in patients with rheumatoid arthritis[J]. Scand J Rheumatol, 2013, 42(2):85-90.
[17]Monney L, Sabatos CA, Gaglia JL, et al. Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease[J]. Nature, 2002, 415(6871):536-541.
[18]Anderson DE. TIM-3 as a therapeutic target in human inflammatory diseases[J]. Expert Opin Ther Targets, 2007, 11(8):1005-1009.
[19]Sabatos CA, Chakravarti S, Cha E, et al. Interaction of Tim-3 and Tim-3 ligand regulates T helper type 1 responses and induction of peripheral tolerance[J]. Nat Immunol, 2003, 4(11):1102-1110.
[20]Fukushima A, Sumi T, Fukuda K, et al. Antibodies to T-cell Ig and mucin domain-containing proteins (Tim)-1 and -3 suppress the induction and progression of murine allergic conjunctivitis[J]. Biochem Biophys Res Commun, 2007, 353(1):211-216.
[21]Sanchez-Fueyo A, Tian J, Picarella D, et al. Tim-3 inhibits T helper type 1-mediated auto- and alloimmune responses and promotes immunological tolerance[J]. Nat Immunol,2003,4(11):1093-1101.
[22]Boenisch O, D’Addio F, Watanabe T, et al. TIM-3: a novel regulatory molecule of alloimmune activation[J]. J Immunol,2010,185(10):5806-5819.
[23]叶雯，王福财，周南进，等. T细胞免疫球蛋白黏蛋白分子-3与消化道肿瘤的研究进展[J]. 医学研究生学报,2016,29(4):435-439.
[24]Ngiow SF, von Scheidt B, Akiba H, et al. Anti-TIM3 antibody promotes T cell IFN-gamma-mediated antitumor immunity and suppresses established tumors[J]. Cancer Res,2011,71(10):3540-3551.
[25]Minn AJ, Wherry EJ. Combination Cancer Therapies with Immune Checkpoint Blockade: Convergence on Interferon Signaling[J]. Cell,2016,165(2):272-275.
[26]Benci JL, Xu B, Qiu Y, et al. Tumor Interferon Signaling Regulates a Multigenic Resistance Program to Immune Checkpoint Blockade[J]. Cell,2016,167(6):1540-1554.
[27]Burstein HJ, Krilov L, Aragon-Ching JB, et al. Clinical Cancer Advances 2017: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology[J]. J Clin Oncol,2017:O2016715292.
[28]Xu Y, Zhang H, Huang Y, et al. Role of TIM-3 in ovarian cancer[J]. Clin Transl Oncol,2017. doi: 10.1007/s12094-017-1656-8. [Epub ahead of print]
[29]Das M, Zhu C, Kuchroo VK. Tim-3 and its role in regulating anti-tumor immunity[J]. Immunol Rev,2017,276(1):97-111.
[30]Schwartz JA, Clayton KL, Mujib S, et al. Tim-3 is a Marker of Plasmacytoid Dendritic Cell Dysfunction during HIV Infection and Is Associated with the Recruitment of IRF7 and p85 into Lysosomes and with the Submembrane Displacement of TLR9[J]. J Immunol, 2017, 198(8):3181-3194.
[31]Wang F, Mao Z, Liu D, et al. Overexpression of Tim-3 reduces Helicobacter pylori-associated inflammation through TLR4/NFkappaB signaling in vitro[J]. Mol Med Rep, 2017, 15(5):3252-3258.
[32]Wang Z, Sun D, Chen G, et al. Tim-3 inhibits macrophage control of Listeria monocytogenes by inhibiting Nrf2[J]. Sci Rep,2017,7:42095.
[33]Liu Y, Cai P, Wang N, et al. Combined blockade of Tim-3 and MEK inhibitor enhances the efficacy against melanoma[J]. Biochem Biophys Res Commun,2017,484(2):378-384.
[34]Yu M, Lu B, Liu Y, et al. Interference with Tim-3 protein expression attenuates the invasion of clear cell renal cell carcinoma and aggravates anoikis[J]. Mol Med Rep,2017,15(3):1103-1108.
[35]Gravelle P, Do C, Franchet C, et al. Impaired functional responses in follicular lymphoma CD8+TIM-3+ T lymphocytes following TCR engagement[J]. Oncoimmunology,2016,5(10):e1224044.
[36]景华. 造血干细胞移植在自身免疫性疾病中的应用进展[J]. 东南国防医药,2010,12(4):322-325.
[37]李颖，刘英娜，覃仕化，等. 类风湿关节炎大鼠模型的相关细胞因子研究[J]. 东南国防医药,2011,13(3):214-216.
[38]Chen J, Sun G, Chen F, et al. T-cell immunoglobulin domain and mucin domain 3 polymorphism affects cytokine expression in different cells and is associated with increased susceptibility to knee osteoarthritis[J]. Gene,2015,566(1):32-36.
[39]Li S, Ren Y, Peng D, et al. TIM-3 Genetic Variations Affect Susceptibility to Osteoarthritis by Interfering with Interferon Gamma in CD4+ T Cells[J]. Inflammation,2015,38(5):1857-1863.
[40]闫峰，黄振平. 调节性T细胞与免疫耐受[J]. 医学研究生学报,2009,22(10):1093-1097.
[41]李颖，刘英娜，覃仕化，等. 类风湿性关节炎患者韧带及关节囊组织炎性浸润机制研究[J]. 东南国防医药,2011,13(4):314-316.
[42]邱一华，谭俊铭，冯金忠，等. 中重度类风湿性关节炎的联合药物治疗比较[J]. 东南国防医药,2007,9(1):14-16, 75

相似文献/References:

[1]房智超,李佳敏,王树楷综述,等.组织驻留巨噬细胞在急性胰腺炎中的作用及靶向干预研究进展[J].医学研究与战创伤救治(原医学研究生学报),2023,25(3):301.[doi:10.3969/j.issn.1672-271X.2023.03.016]
　FANG Zhichao,LI Jiamin,WANG Shukai,et al.Advances in the role of tissue-resident macrophages in acute pancreatitis and targeted intervention[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2023,25(04):301.[doi:10.3969/j.issn.1672-271X.2023.03.016]

备注/Memo

备注/Memo:
基金项目：南京军区科技创新项目(15ZD020)；南京市科技计划项目(201503007)
更新日期/Last Update: 2017-07-20